Paras D. Shah

Array ( [id] => 18649479 [patent_doc_number] => 20230295292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/052172 [patent_app_country] => US [patent_app_date] => 2022-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19684055 [patent_doc_number] => 20250002600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 18/696689 [patent_app_country] => US [patent_app_date] => 2022-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -83 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18696689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18264592 [patent_doc_number] => 20230085834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => Chimeric Antigen Receptors Comprising Interleukin-9 Receptor Signaling Domain [patent_app_type] => utility [patent_app_number] => 17/933049 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077428 [patent_doc_number] => 20220403040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/822750 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18496211 [patent_doc_number] => 20230218775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS) [patent_app_type] => utility [patent_app_number] => 17/821854 [patent_app_country] => US [patent_app_date] => 2022-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18076141 [patent_doc_number] => 20220401753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => METHODS OF INCREASING RESPONSE TO CANCER RADIATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/818854 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18466875 [patent_doc_number] => 20230201155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 [patent_app_type] => utility [patent_app_number] => 17/871397 [patent_app_country] => US [patent_app_date] => 2022-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18279395 [patent_doc_number] => 20230094867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/825244 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17825244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958613 [patent_doc_number] => 20220339193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => Modified Cell Expressing Therapeutic Agent and Uses thereof [patent_app_type] => utility [patent_app_number] => 17/749824 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20547633 [patent_doc_number] => 12558406 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Anti-TIGIT antibodies and use thereof [patent_app_type] => utility [patent_app_number] => 18/290171 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 51 [patent_no_of_words] => 15026 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18290171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19249106 [patent_doc_number] => 20240200093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => ARTIFICIAL REGULATORY CASSETTES FOR MUSCLE-SPECIFIC GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 18/286215 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497680 [patent_doc_number] => 20240336698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => CD38 Chimeric Co-Stimulating Receptor and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/283547 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125804 [patent_doc_number] => 20240131157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/546302 [patent_app_country] => US [patent_app_date] => 2022-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125804 [patent_doc_number] => 20240131157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/546302 [patent_app_country] => US [patent_app_date] => 2022-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376019 [patent_doc_number] => 20230151101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => METHODS AND COMPOSITIONS TO ENHANCE HUMORAL IMMUNITY TO REDUCE CYTOMEGALOVIRUS INFECTION AND REACTIVATION BY IL-6 INHIBITION [patent_app_type] => utility [patent_app_number] => 17/573572 [patent_app_country] => US [patent_app_date] => 2022-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464196 [patent_doc_number] => 20240317865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1 [patent_app_type] => utility [patent_app_number] => 18/258189 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670958 [patent_doc_number] => 20220184125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => S309 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/551006 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17551006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988783 [patent_doc_number] => 20220354820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 [patent_app_type] => utility [patent_app_number] => 17/548340 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398209 [patent_doc_number] => 20220040299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => METHODS OF TREATING CROHN'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/507414 [patent_app_country] => US [patent_app_date] => 2021-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503277 [patent_doc_number] => 20220096379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => SELF-EMULSIFYING DRUG FORMULATION FOR IMPROVING MEMBRANE PERMEABILITY OF COMPOUND [patent_app_type] => utility [patent_app_number] => 17/502525 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502525 [rel_patent_id] =>[rel_patent_doc_number] =>)